Loading
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.
Shares PSMAfore, VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan.
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares VISION, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.